<?xml version='1.0' encoding='utf-8'?>
<document id="24602156"><sentence text="Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies."><entity charOffset="57-69" id="DDI-PubMed.24602156.s1.e0" text="mericitabine" /></sentence><sentence text="The aim was to evaluate early viral kinetics in patients receiving mericitabine [hepatitis C virus (HCV) nucleoside polymerase inhibitor] with peginterferon alfa-2a (40KD) and ribavirin in two clinical trials (PROPEL and JUMP-C)"><entity charOffset="67-79" id="DDI-PubMed.24602156.s2.e0" text="mericitabine" /><entity charOffset="176-185" id="DDI-PubMed.24602156.s2.e1" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.24602156.s2.e0" e2="DDI-PubMed.24602156.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24602156.s2.e0" e2="DDI-PubMed.24602156.s2.e1" /></sentence><sentence text="" /><sentence text="We examined rapid virological responses (RVRs; week 4 HCV RNA &lt;15 IU ml(-1) ) and complete early virological responses (cEVR; week 12 HCV RNA &lt;15 IU ml(-1) ) in HCV genotype 1/4-infected patients receiving mericitabine (500 or 1000 mg) or placebo twice daily plus peginterferon alfa-2a and ribavirin"><entity charOffset="206-218" id="DDI-PubMed.24602156.s4.e0" text="mericitabine" /><entity charOffset="290-299" id="DDI-PubMed.24602156.s4.e1" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.24602156.s4.e0" e2="DDI-PubMed.24602156.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24602156.s4.e0" e2="DDI-PubMed.24602156.s4.e1" /></sentence><sentence text="" /><sentence text="Among IL28B rs12979860 CC genotype patients receiving 500 or 1000 mg mericitabine or placebo, respectively, RVR rates were 64"><entity charOffset="69-81" id="DDI-PubMed.24602156.s6.e0" text="mericitabine" /></sentence><sentence text="3% (95% confidence interval: 38" /><sentence text="8-83" /><sentence text="7%), 95" /><sentence text="1% (83" /><sentence text="9-98" /><sentence text="7%) and 33" /><sentence text="3% (20" /><sentence text="2-49" /><sentence text="7%), and cEVR rates were 100% (78" /><sentence text="5-100%), 100% (91" /><sentence text="4-100%) and 80" /><sentence text="6% (65" /><sentence text="0-90" /><sentence text="3%)" /><sentence text=" Among non-CC genotype patients, RVR rates were 26" /><sentence text="5% (14" /><sentence text="6-43" /><sentence text="1%), 52" /><sentence text="3% (43" /><sentence text="0-61" /><sentence text="3%) and 5" /><sentence text="7% (2" /><sentence text="2-13" /><sentence text="8%), and cEVR rates were 76" /><sentence text="5% (60" /><sentence text="0-87" /><sentence text="6%), 84" /><sentence text="6% (76" /><sentence text="6-90" /><sentence text="1%) and 28" /><sentence text="6% (19" /><sentence text="3-40" /><sentence text="1%), respectively" /><sentence text=" In multiple regression analysis, IL28B genotype (P &lt; 0" /><sentence text="0001), mericitabine dose (P &lt; 0"><entity charOffset="7-19" id="DDI-PubMed.24602156.s41.e0" text="mericitabine" /></sentence><sentence text="0001) and bodyweight (P = 0" /><sentence text="0009) were associated with first-phase (α) slope (change in log10 HCV RNA from baseline to week 1)" /><sentence text="" /><sentence text="Mericitabine-containing triple therapy reduces the impact of IL28B genotype on RVR and cEVR compared with peginterferon alfa-2a and ribavirin dual therapy"><entity charOffset="0-12" id="DDI-PubMed.24602156.s45.e0" text="Mericitabine" /><entity charOffset="132-141" id="DDI-PubMed.24602156.s45.e1" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.24602156.s45.e0" e2="DDI-PubMed.24602156.s45.e0" /><pair ddi="false" e1="DDI-PubMed.24602156.s45.e0" e2="DDI-PubMed.24602156.s45.e1" /></sentence><sentence text=" The IL28B genotype, mericitabine dose and bodyweight are the most important factors associated with the α slope, and there is no evidence of a pharmacokinetic drug-drug interaction between mericitabine and ribavirin"><entity charOffset="21-33" id="DDI-PubMed.24602156.s46.e0" text="mericitabine" /><entity charOffset="190-202" id="DDI-PubMed.24602156.s46.e1" text="mericitabine" /><entity charOffset="207-216" id="DDI-PubMed.24602156.s46.e2" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.24602156.s46.e0" e2="DDI-PubMed.24602156.s46.e0" /><pair ddi="false" e1="DDI-PubMed.24602156.s46.e0" e2="DDI-PubMed.24602156.s46.e1" /><pair ddi="false" e1="DDI-PubMed.24602156.s46.e0" e2="DDI-PubMed.24602156.s46.e2" /><pair ddi="false" e1="DDI-PubMed.24602156.s46.e1" e2="DDI-PubMed.24602156.s46.e1" /><pair ddi="false" e1="DDI-PubMed.24602156.s46.e1" e2="DDI-PubMed.24602156.s46.e2" /></sentence><sentence text="" /></document>